Abstract
It is of great significance to monitor therapeutic antibodies in human serum to obtain the pharmacokinetic data for assessing their therapeutic efficacy at the dosage of administration. Here, based on the target-triggered proximity binding approach, as well as the catalytic hairpin assembly (CHA) and CRISPR/Cas12a cleavage dual signal amplification strategy, we describe the establishment of a highly sensitive method for detecting panitumumab, a cancer therapeutic monoclonal antibody, in diluted human serums. The two proximity probes bind the target panitumumab simultaneously to form initiation sequences for subsequent CHA for the cyclic yield of many dsDNAs, which further activate the specific trans-cleavage activity of Cas12a to digest lots of fluorescently quenched ssDNAs to restore drastically enhanced fluorescence for detecting panitumumab with a 0.62 pM detection limit. Besides, the sensing approach can selectively discriminate panitumumab against other monoclonal antibodies and realize low levels of panitumumab detection in diluted serums. Moreover, by simple replacement of the proximity recognition probes, the established method can be easily expanded for the development of versatile sensing platforms for different biomolecules in addition to antibodies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
